Neugroschl Judith, Sano Mary
James J. Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA.
Curr Neurol Neurosci Rep. 2009 Sep;9(5):368-76. doi: 10.1007/s11910-009-0054-1.
With the aging of the population, the incidence and prevalence of Alzheimer's disease will grow, increasing the burden on individuals and society. While ameliorating symptoms, the currently available treatments approved by the US Food and Drug Administration do not halt progression or cure the illness. This article discusses recent data on treatment strategies targeting amyloid and tau pathology. Novel therapeutic strategies such as inhibitors of receptors for advanced glycation end products (RAGE), potential mitochondrial modification with Dimebon, anti-inflammatory approaches, and cholesterol-lowering agents are also reviewed. An update on results from pharmacologic and nonpharmacologic prevention trials is provided.
随着人口老龄化，阿尔茨海默病的发病率和患病率将会上升，这将增加个人和社会的负担。尽管美国食品药品监督管理局批准的现有治疗方法能够缓解症状，但并不能阻止疾病进展或治愈该病。本文讨论了针对淀粉样蛋白和tau蛋白病变的治疗策略的最新数据。还综述了新型治疗策略，如晚期糖基化终末产物受体（RAGE）抑制剂、用二甲金刚胺进行潜在的线粒体修饰、抗炎方法以及降胆固醇药物。本文还提供了药物和非药物预防试验结果的最新情况。
